SCHEMBL15928709

SCHEMBL15928709

Cc1cccc(-c2cc(F)c(NC(=O)c3ccccc3C(=O)O)c(Cl)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.54
AKR1C1 Q04828 1/20 0.54
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
KMT2A Q03164 1/20 0.53
FTO Q9C0B1 5/20 0.51
POLB P06746 1/20 0.50
DHODH Q02127 4/20 0.46
MAPK1 P28482 1/20 0.46
GFER P55789 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
PTPRC P08575 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPA Q15257 1/20 0.44
PTGER4 P35408 1/20 0.43
PTGER2 P43116 1/20 0.43
HCAR2 Q8TDS4 1/20 0.43
SMO Q99835 1/20 0.43
KCNK3 O14649 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15928790 0.92 MEN1 (0.59) AKR1C2AKR1C1MEN1ALDH1A1KMT2A
SCHEMBL12127527 0.86 AKR1C2 (0.43) AKR1C2AKR1C1FTODHODHL3MBTL1
SCHEMBL1337018 0.86 DHODH (0.48) KMT2AFTOPOLBDHODHL3MBTL1
SCHEMBL1335669 0.83 DHODH (0.69) DHODHL3MBTL1PTPRCPTPN2PTPN1
SCHEMBL12127412 0.83 AKR1C2 (0.41) AKR1C2AKR1C1MEN1ALDH1A1KMT2A
SCHEMBL1336883 0.83 DHODH (0.50) FTODHODH
SCHEMBL1337680 0.82 DHODH (0.63) DHODH
SCHEMBL1336938 0.81 DHODH (0.59) MEN1ALDH1A1KMT2ADHODHL3MBTL1
SCHEMBL1337527 0.81 KDM4E (0.52) MEN1ALDH1A1KMT2AFTODHODH
SCHEMBL1336461 0.81 KDM4E (0.49) MEN1ALDH1A1KMT2AFTODHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR AKR1C2 160/4885AKR1C1 208/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.